← board
MTNB
distress 9/10 · high distress / dilution risk$0.25-8%today-90% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
0.4 yrs
Shares 1y
+26%
Price & events
-58.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-7.8%
1D
-31.0%
1W
-62.1%
1M
-60.1%
3M
-65.8%
6M
-74.1%
1Y
-97.1%
2Y
-99.3%
5Y
-99.7%
All
Overview
- Market Cap
- $1.58M
- Volume
- 82.56K
- 52 Week Range
- $0.25 – $2.36
- Total Shares
- 6.41M
- Float Shares
- 4.18M
- Short %
- 0.10%
- % Held by Insiders
- 10.34%
- % Held by Institutions
- 2.59%
- RVOL
- 0.10x
- Beta
- 1.71
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2024-10-31trial discontinuedMAT2203 · All product development activities ceased, including MAT2203 Phase 3 registration trial planning.SEC 8-K
- 2024-10-31withdrawalMAT2203 · Partnership negotiations terminated following notification from prospective partner.SEC 8-K
- 2024-08-14partnershipMAT2203 · Signed non-binding term sheet for global licensing rights to develop and commercialize MAT2203SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-10-31Maxim GroupBuy → Hold
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.